• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌:64例临床病理研究

Hepatocellular carcinoma: a clinicopathological study of 64 cases.

作者信息

Limaiem Faten, Bouhamed Marwa, Sahraoui Ghada, Mzabi Sabeh

机构信息

Université de Tunis El Manar, Faculté de Médecine de Tunis, 1007.

出版信息

Pan Afr Med J. 2017 May 16;27:41. doi: 10.11604/pamj.2017.27.41.9584. eCollection 2017.

DOI:10.11604/pamj.2017.27.41.9584
PMID:28761617
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5516652/
Abstract

Hepatocellular carcinoma (HCC) is the most common of all liver cancers and is a major worldwide public health problem. The aim of this study was to provide an updated overview on clinicopathological features, treatment and outcome of HCC. In our retrospective study, we reviewed 64 cases of HCC that were diagnosed at the pathology department of Mongi Slim hospital over a fifteen-year period (2000- 2014). Relevant clinical information and microscopic slides were retrospectively reviewed. Our study group included 38 men and 26 women (sex ratio M/F = 1,26) aged between 8 and 83 years (mean = 56,64 years). The presenting clinical symptoms were dominated by abdominal pain (n=34), followed by altered general health (n=25) and jaundice (n=4). Fifty-five patients underwent surgical treatment. Liver transplantation was performed in two cases and transarterial chemoembolization was achieved in seven cases. Histopathological examination of the surgical or biopsy specimen established the diagnosis of conventional HCC in 55 cases, fibrolamellar carcinoma in 6 cases and clear cell HCC in 3 cases. Seven patients with HCC died postoperatively. Local recurrence of the tumour occurred in three cases and two patients had distant metastases postoperatively. The other patients are still being followed-up. Hepatocellular carcinoma is associated with a high rate of mortality because of early invasion, widespread metastasis and lack of effective therapeutic modalities. Accurate diagnosis and staging of these tumours is critical for optimal treatment planning and for determining prognosis.

摘要

肝细胞癌(HCC)是所有肝癌中最常见的类型,也是全球主要的公共卫生问题。本研究的目的是提供关于HCC临床病理特征、治疗及预后的最新概述。在我们的回顾性研究中,我们回顾了蒙吉·斯利姆医院病理科在15年期间(2000年至2014年)诊断的64例HCC病例。对相关临床信息和显微镜载玻片进行了回顾性分析。我们的研究组包括38名男性和26名女性(男女比例为1.26),年龄在8岁至83岁之间(平均年龄为56.64岁)。主要临床症状以腹痛为主(n = 34),其次是一般健康状况改变(n = 25)和黄疸(n = 4)。55例患者接受了手术治疗。2例行肝移植,7例行经动脉化疗栓塞术。手术或活检标本的组织病理学检查确诊55例为传统型HCC,6例为纤维板层癌,3例为透明细胞HCC。7例HCC患者术后死亡。3例出现肿瘤局部复发,2例术后发生远处转移。其他患者仍在随访中。由于早期侵袭、广泛转移以及缺乏有效的治疗方式,肝细胞癌的死亡率很高。对这些肿瘤进行准确的诊断和分期对于优化治疗方案和判断预后至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16ab/5516652/e4269c033436/PAMJ-27-41-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16ab/5516652/9148738fc332/PAMJ-27-41-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16ab/5516652/76a784e94510/PAMJ-27-41-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16ab/5516652/275fff587aa6/PAMJ-27-41-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16ab/5516652/e4269c033436/PAMJ-27-41-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16ab/5516652/9148738fc332/PAMJ-27-41-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16ab/5516652/76a784e94510/PAMJ-27-41-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16ab/5516652/275fff587aa6/PAMJ-27-41-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16ab/5516652/e4269c033436/PAMJ-27-41-g004.jpg

相似文献

1
Hepatocellular carcinoma: a clinicopathological study of 64 cases.肝细胞癌:64例临床病理研究
Pan Afr Med J. 2017 May 16;27:41. doi: 10.11604/pamj.2017.27.41.9584. eCollection 2017.
2
Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program.在肝移植项目中,经动脉化疗栓塞联合载药微球治疗的肝细胞癌患者当日出院的安全性和可行性。
J Vasc Interv Radiol. 2014 Jul;25(7):1012-7. doi: 10.1016/j.jvir.2014.02.025. Epub 2014 Apr 3.
3
Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.对超出米兰标准的肝细胞癌患者进行降期治疗:使用载药微球化疗栓塞的策略
J Vasc Interv Radiol. 2013 Nov;24(11):1613-22. doi: 10.1016/j.jvir.2013.07.024. Epub 2013 Sep 20.
4
Fibrolamellar carcinoma versus scirrhous hepatocellular carcinoma : diagnostic usefulness of CD68.纤维板层癌与硬化型肝细胞癌:CD68的诊断价值
Acta Gastroenterol Belg. 2015 Dec;78(4):393-8.
5
Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.肝细胞癌合并胆管细胞癌:临床特征、治疗方式和预后。
Ann Surg Oncol. 2012 Sep;19(9):2869-76. doi: 10.1245/s10434-012-2328-0. Epub 2012 Mar 27.
6
Pre-transplant therapy for hepatocellular carcinoma is associated with a lower recurrence after liver transplantation.肝移植前治疗肝癌可降低肝移植后的复发率。
Clin Transplant. 2009 Nov-Dec;23(6):874-81. doi: 10.1111/j.1399-0012.2009.00993.x. Epub 2009 May 4.
7
Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.巴塞罗那临床肝癌分期0/A期切除术后复发性肝细胞癌经动脉化疗栓塞术与射频消融术的回顾性对比研究
J Vasc Interv Radiol. 2016 Dec;27(12):1829-1836. doi: 10.1016/j.jvir.2016.06.010. Epub 2016 Aug 21.
8
The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis.代谢肿瘤体积在无肝外转移的肝细胞癌患者中对氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG PET/CT)引导下经动脉化疗栓塞术和经动脉化疗灌注术的预测价值。
Ann Nucl Med. 2015 Jun;29(5):400-8. doi: 10.1007/s12149-015-0956-8. Epub 2015 Feb 5.
9
Which system is better to predict prognosis of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization as initial therapy? Comparison between CLIP and JIS in a Japanese population.对于经动脉化疗栓塞术作为初始治疗的肝细胞癌患者,哪种系统更适合预测其预后?日本人群中CLIP与JIS的比较。
Acta Radiol. 2016 Dec;57(12):1445-1452. doi: 10.1177/0284185116628339. Epub 2016 Jul 19.
10
Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.载阿霉素超吸收性聚合物微球经导管动脉化疗栓塞治疗肝细胞癌的中期随访
J Vasc Interv Radiol. 2014 Feb;25(2):248-55.e1. doi: 10.1016/j.jvir.2013.10.017. Epub 2013 Dec 2.

引用本文的文献

1
Current Advances in the Treatment of Fibrolamellar Carcinoma of Liver.肝纤维板层癌治疗的当前进展
J Hepatocell Carcinoma. 2023 May 15;10:745-752. doi: 10.2147/JHC.S406902. eCollection 2023.
2
Does Type 2 Diabetes Increase the Risk of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease Patients? A Systematic Review.2型糖尿病会增加非酒精性脂肪性肝病患者患肝细胞癌的风险吗?一项系统评价。
Cureus. 2023 Mar 13;15(3):e36079. doi: 10.7759/cureus.36079. eCollection 2023 Mar.
3
Treatment and Prognosis of Fibrolamellar Hepatocellular Carcinoma: a Systematic Review of the Recent Literature and Meta-analysis.

本文引用的文献

1
Hepatocellular carcinoma: A global view.肝细胞癌:全球视角。
Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):448-58. doi: 10.1038/nrgastro.2010.100. Epub 2010 Jul 13.
2
Loco-regional treatment of hepatocellular carcinoma.局部区域治疗肝细胞癌。
Hepatology. 2010 Aug;52(2):762-73. doi: 10.1002/hep.23725.
3
Molecular mechanisms of hepatocellular carcinoma.肝细胞癌的分子机制
纤维板层肝细胞癌的治疗与预后:近期文献的系统评价和荟萃分析。
J Gastrointest Surg. 2023 Apr;27(4):705-715. doi: 10.1007/s11605-023-05621-z. Epub 2023 Feb 16.
Hepatology. 2008 Dec;48(6):2047-63. doi: 10.1002/hep.22580.
4
Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology.日本肝细胞癌的管理:日本肝脏学会提出的基于共识的临床实践手册
Oncology. 2007;72 Suppl 1:2-15. doi: 10.1159/000111702. Epub 2007 Dec 13.
5
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.肝细胞癌:流行病学与分子致癌机制
Gastroenterology. 2007 Jun;132(7):2557-76. doi: 10.1053/j.gastro.2007.04.061.
6
Review of the clinicopathologic features of fibrolamellar carcinoma.纤维板层癌的临床病理特征综述。
Adv Anat Pathol. 2007 May;14(3):217-23. doi: 10.1097/PAP.0b013e3180504913.
7
Management of hepatocellular carcinoma.肝细胞癌的管理
Hepatology. 2005 Nov;42(5):1208-36. doi: 10.1002/hep.20933.
8
Spontaneous regression of hepatocellular carcinoma: two case reports and a literature review.
Hepatol Res. 2004 Jul;29(3):180-190. doi: 10.1016/j.hepres.2004.03.005.
9
Progress in surgical treatment of hepatocellular carcinoma.肝细胞癌外科治疗的进展
Oncology. 2002;62 Suppl 1:74-81. doi: 10.1159/000048280.
10
Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation.肝细胞癌的非手术治疗:从经皮乙醇注射疗法、经皮微波凝固疗法到射频消融术。
Oncology. 2002;62 Suppl 1:64-8. doi: 10.1159/000048278.